Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

Abstract Introduction Prior research has demonstrated that early treatment with high-efficacy disease-modifying therapies (DMTs), including ocrelizumab (OCR), can reduce relapses and delay disease progression among persons with multiple sclerosis (pwMS) compared with escalation from low-/moderate-ef...

Full description

Bibliographic Details
Main Authors: Caroline K. Geiger, Danny Sheinson, Tu My To, David Jones, Nicole G. Bonine
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-07-01
Series:Neurology and Therapy
Subjects:
Claims database
Disease-modifying therapies
Early treatment
Healthcare costs
Healthcare resource use
Multiple sclerosis
Online Access:https://doi.org/10.1007/s40120-023-00523-3

Internet

https://doi.org/10.1007/s40120-023-00523-3

Similar Items